Celldex Therapeutics (NASDAQ:CLDX) slipped in premarket trading on Wednesday after releasing results from its Phase 2 study of Barzolvolimab in patients with eosinophilic esophagitis (EoE), a chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback